Dr. Richard Kornbluth is an immunologist, physician, and serial entrepreneur. Richard trained at Harvard (A.B.), New York Medical College (M.D.), Columbia University (Ph.D.), and the Scripps Research Institute (postdoc). He was a faculty member at Univ. Calif. San Diego where he worked on HIV vaccines and immunology. He founded Multimeric Biotherapeutics, Inc. to develop the technology he invented for making highly active, soluble TNF SuperFamily ligands (TNFSFs), focusing on CD40L which is a powerful activator of dendritic cells. In collaboration with Geoffrey W. Stone, Ph.D. (his former post-doc), he developed FortiVac™ as a next generation vaccine technology for eliciting very strong CD8+ T cell responses against viruses and cancer.